| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michele Salemi, Federico Ridolfo, Maria Grazia Salluzzo, Francesca A Schillaci, Salvatore Caniglia, Bartolo Lanuzza, Mariagiovanna Cantone, Raffaele Ferr. Humanin gene expression in subjects with Parkinson's disease. Molecular biology reports. 2023-01-10. PMID:36626066. |
the peculiar pathological features of pd are decreased dopaminergic neurons and dopamine levels in the substantia nigra pars compacta and pontine locus coeruleus. |
2023-01-10 |
2023-08-14 |
human |
| Nilima Prakas. Developmental pathways linked to the vulnerability of adult midbrain dopaminergic neurons to neurodegeneration. Frontiers in molecular neuroscience. vol 15. 2023-01-09. PMID:36618829. |
despite the remarkable ability of the brain to compensate such dopamine deficits, the early loss or dysfunction of these neurons might predispose an individual to suffer from pd because the critical threshold of dopamine function will be reached much earlier in life, even if the time-course and strength of naturally occurring and age-dependent dopaminergic cell death is not markedly altered in this individual. |
2023-01-09 |
2023-08-14 |
Not clear |
| Anna Kolacheva, Alyona Bannikova, Ekaterina Pavlova, Vsevolod Bogdanov, Michael Ugrumo. Modeling of the Progressive Degradation of the Nigrostriatal Dopaminergic System in Mice to Study the Mechanisms of Neurodegeneration and Neuroplasticity in Parkinson's Disease. International journal of molecular sciences. vol 24. issue 1. 2023-01-08. PMID:36614126. |
this model reproduces the main hallmarks of pd: progressive degeneration of dopaminergic neurons; the appearance of motor disorders with a 70-80% decrease in the level of dopamine in the striatum; an increase in dopamine turnover in the striatum to compensate for dopamine deficiency. |
2023-01-08 |
2023-08-14 |
mouse |
| Sergei V Beliakov, Victor Blokhin, Sergey A Surkov, Michael V Ugrumo. LUHMES Cells: Phenotype Refinement and Development of an MPP International journal of molecular sciences. vol 24. issue 1. 2023-01-08. PMID:36614176. |
luhmes cells: phenotype refinement and development of an mpp the low effectiveness of symptomatic pharmacotherapy for parkinson's disease (pd), which compensates for dopamine (da) deficiency under degeneration of nigrostriatal dopaminergic (daergic) neurons, could apparently be improved with neuroprotective therapy, which slows down neurodegeneration and pd progression. |
2023-01-08 |
2023-08-14 |
human |
| Mirjam Wolfschlag, Anders Håkansso. Drug-Induced Gambling Disorder: Epidemiology, Neurobiology, and Management. Pharmaceutical medicine. 2023-01-07. PMID:36611111. |
since reward-related learning is mediated by dopamine, it can be altered by dopaminergic medications, possibly leading to increased gambling behavior and a decreased impulse control. |
2023-01-07 |
2023-08-14 |
Not clear |
| Susanna Molas, Rubing Zhao-Shea, Timothy G Freels, Andrew R Tappe. Viral tracing confirms paranigral ventral tegmental area dopaminergic inputs to the interpeduncular nucleus where dopamine release encodes motivated exploration. eNeuro. 2023-01-04. PMID:36599671. |
viral tracing confirms paranigral ventral tegmental area dopaminergic inputs to the interpeduncular nucleus where dopamine release encodes motivated exploration. |
2023-01-04 |
2023-08-14 |
mouse |
| Esen Saka Topçuoğlu, Ümit Özgür Akdemir, Lütfiye Özlem Ata. What is New in Nuclear Medicine Imaging for Dementia. Noro psikiyatri arsivi. vol 59. issue Suppl 1. 2022-12-29. PMID:36578980. |
amyloid positron emission tomography (pet) and tau pet, which are molecular imaging methods, [f18]fluorodeoxyglucose (fdg) pet showing the glucose metabolism pattern in the brain, dopamine transporter single photon emission computerized tomography (spect) that marks dopaminergic terminals are valuable tools for early recognition and differentiation of ad and its atypical variants, frontotemporal dementias and dementia with lewy bodies. |
2022-12-29 |
2023-08-14 |
Not clear |
| Xing-Jie Xu, Tao Pan, Hui-Jie Fan, Xu Wang, Jie-Zhong Yu, Hai-Fei Zhang, Bao-Guo Xiao, Zhen-Yu Li, Bo Zhang, Cun-Gen Ma, Zhi Cha. Neuroprotective effect of hyperoside in MPP Metabolic brain disease. 2022-12-28. PMID:36576692. |
neuroprotective effect of hyperoside in mpp parkinson's disease (pd) is a neurodegenerative disease characterized by the pathological loss of nigrostriatal dopaminergic neurons, which causes an insufficient release of dopamine (da) and then induces motor and nonmotor symptoms. |
2022-12-28 |
2023-08-14 |
Not clear |
| Tahereh Ghaedian, Ali Razmkon, Leila Kalhor, Vahid Reza Ostovan, Omid Yousefi, Raziyeh Rezaei, Mohammad Reza Hossein-Tehrani, Abbas Rakhsh. Correlation of response to subthalamic deep brain stimulation in Parkinson's disease patients with striatal dopamine transporter density on 99mtc-TRODAT-1 SPECT. Neurological research. 2022-12-27. PMID:36573915. |
since the loss of dopaminergic neurons in the substantia nigra is the main pathophysiology of pd, we aimed to evaluate the association of response to dbs with preoperative dopamine transporter density (dat) and its postoperative changes in pd patients who underwent the bilateral implantation of the electrodes in the subthalamic nucleus (stn). |
2022-12-27 |
2023-08-14 |
Not clear |
| Dmitry Troshev, Victor Blokhin, Valeria Ukrainskaya, Anna Kolacheva, Michael Ugrumo. Isolation of living dopaminergic neurons labeled with a fluorescent ligand of the dopamine transporter from mouse substantia nigra as a new tool for basic and applied research. Frontiers in molecular neuroscience. vol 15. 2022-12-26. PMID:36568278. |
isolation of living dopaminergic neurons labeled with a fluorescent ligand of the dopamine transporter from mouse substantia nigra as a new tool for basic and applied research. |
2022-12-26 |
2023-08-14 |
mouse |
| Dmitry Troshev, Victor Blokhin, Valeria Ukrainskaya, Anna Kolacheva, Michael Ugrumo. Isolation of living dopaminergic neurons labeled with a fluorescent ligand of the dopamine transporter from mouse substantia nigra as a new tool for basic and applied research. Frontiers in molecular neuroscience. vol 15. 2022-12-26. PMID:36568278. |
we have developed a method for selecting a population of dns from the sn of mice, as evidenced by: (i) immunopositivity of 95% of the sorted cells for tyrosine hydroxylase, the first enzyme of dopamine synthesis; (ii) the sorted cells expressing the genes for specific proteins of the dopaminergic phenotype, tyrosine hydroxylase, the dopamine transporter, and vesicular monoamine transporter 2 and non-specific proteins, such as aromatic l-amino acid decarboxylase, non-specific enzyme of dopamine synthesis. |
2022-12-26 |
2023-08-14 |
mouse |
| Dewei Ye, Jiating Huang, Jiaming Wu, Kang Xie, Xiang Gao, Kaixuan Yan, Pengfei Zhang, Ying Tao, Yun Li, Shufei Zang, Xianglu Rong, Jun Li, Jiao Gu. Integrative metagenomic and metabolomic analyses reveal gut microbiota-derived multiple hits connected to development of gestational diabetes mellitus in humans. Gut microbes. vol 15. issue 1. 2022-12-23. PMID:36550785. |
blood metabolite profiles revealed that gdm patients exhibited a marked increase in 2-hydroxybutyric acid and l-alpha-aminobutyric acid, but a decrease in methionine sulfoxide, allantoin, and dopamine and dopaminergic synapse, when compared with those in ngt controls. |
2022-12-23 |
2023-08-14 |
Not clear |
| Giselle Prunell, Silvia Olivera-Brav. A Focus on Astrocyte Contribution to Parkinson's Disease Etiology. Biomolecules. vol 12. issue 12. 2022-12-23. PMID:36551173. |
parkinson's disease (pd) is an incurable neurodegenerative disease of high prevalence, characterized by the prominent death of dopaminergic neurons in the substantia nigra pars compacta, which produces dopamine deficiency, leading to classic motor symptoms. |
2022-12-23 |
2023-08-14 |
Not clear |
| Ilya S Zhukov, Anastasia N Vaganova, Ramilya Z Murtazina, Lyubov S Alferova, Elena I Ermolenko, Raul R Gainetdino. Gut Microbiota Alterations in Trace Amine-Associated Receptor 9 (TAAR9) Knockout Rats. Biomolecules. vol 12. issue 12. 2022-12-23. PMID:36551251. |
additionally, taar9 was co-expressed with genes implicated in dopamine signaling, which may suggest a role for this receptor in the regulation of peripheral dopaminergic transmission. |
2022-12-23 |
2023-08-14 |
rat |
| Juan Carlos Magaña, Cláudia M Deus, Maria Giné-Garriga, Joel Montané, Susana P Pereir. Exercise-Boosted Mitochondrial Remodeling in Parkinson's Disease. Biomedicines. vol 10. issue 12. 2022-12-23. PMID:36551984. |
parkinson's disease (pd) is a movement disorder characterized by the progressive degeneration of dopaminergic neurons resulting in dopamine deficiency in the |
2022-12-23 |
2023-08-14 |
Not clear |
| Jace Jones-Taba. Targeting G protein-coupled receptors in the treatment of Parkinson's disease. Journal of molecular biology. 2022-12-23. PMID:36563742. |
first, we discuss new developments in dopaminergic agents for alleviating pd motor impairment, the role of dopamine receptors in l-dopa induced dyskinesia, as well as agents targeting non-dopamine gpcrs which could augment or replace traditional dopaminergic treatments. |
2022-12-23 |
2023-08-14 |
Not clear |
| Obaydah Abd Alkader Alabrahim, Hassan Mohamed El-Said Azzaz. Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease. Nanoscale advances. vol 4. issue 24. 2022-12-21. PMID:36540116. |
the continuous loss of dopaminergic neurons and the concomitant brain depletion of dopamine levels represent the hallmarks of pd. |
2022-12-21 |
2023-08-14 |
Not clear |
| Changcheng Lu, Shuhui Qu, Zhangfeng Zhong, Hua Luo, Si San Lei, Hai-Jing Zhong, Huanxing Su, Yitao Wang, Cheong-Meng Chon. The effects of bioactive components from the rhizome of Frontiers in pharmacology. vol 13. 2022-12-19. PMID:36532787. |
pd drugs mainly enhance dopamine levels but cannot prevent or slow down the loss of dopaminergic neurons. |
2022-12-19 |
2023-08-14 |
Not clear |
| Yara T Mohamed, Abeer Salama, Mostafa A Rabie, Mai A Abd El Fatta. Neuroprotective effect of secukinumab against rotenone induced Parkinson's disease in rat model: Involvement of IL-17, HMGB-1/TLR4 axis and BDNF/TrKB cascade. International immunopharmacology. vol 114. 2022-12-17. PMID:36527875. |
furthermore, secukinumab increased striatal tyrosine hydroxylase immunoexpression, the rate limiting step in dopamine biosynthesis, to guard against dopaminergic neuronal loss. |
2022-12-17 |
2023-08-14 |
rat |
| Zamira M Muruzheva, Daniil S Egorov, Margarita T Absalyamova, Dmitrii S Traktirov, Marina N Karpenko, Serguei O Fetisso. Neurotensin-Binding Immunoglobulin G in Patients with Parkinson's Disease. Neuroimmunomodulation. 2022-12-14. PMID:36516809. |
neurotensin (nts) is a 13-amino acid neuropeptide functionally linked with the brain dopaminergic system via expression of the nts peptide or its receptor in dopamine neurons. |
2022-12-14 |
2023-08-14 |
Not clear |